Lexicon Pharma Q3 net loss narrows as R&D costs drops

Lexicon Pharmaceuticals

06/11/2025 12:39

Overview

Lexicon Q3 2025 total revenue increased to $14.2 mln, driven by licensing revenue

Net loss for Q3 2025 was $12.8 mln, significantly lower than Q3 2024

R&D expenses decreased to $18.8 mln due to lower external research costs

Outlook

Lexicon expects 2026 to be pivotal for strategic initiatives

FDA feedback on Zynquista resubmission expected in Q4 2025

Novo Nordisk preparing IND submission for LX9851, triggering potential milestone payments

Result Drivers

LICENSING REVENUE - Increase in Q3 2025 revenue attributed to licensing agreement with Novo Nordisk

EXPENSE REDUCTION - Decrease in R&D and SG&A expenses due to strategic repositioning and reduced marketing efforts

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$1.01 mln
Q3 EPS
-$0.04
Q3 Net Income
-$12.77 mln
Q3 Basic EPS
-$0.04
Q3 Operating Expenses
$26.37 mln
Q3 Operating Income
-$12.19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.90, about 27.4% above its November 5 closing price of $1.38

Press Release: ID:nGNX8DQckG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)